Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
about
Major clinical research advances in gynecologic cancer in 2013Advances in diagnosis and treatment of metastatic cervical cancerDifferent strategies of treatment for uterine cervical carcinoma stage IB2-IIBMulticenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.Brachytherapy in the treatment of cervical cancer: a review.Analysis of morbidity and clinical implications of laparoscopic para-aortic lymphadenectomy in a continuous series of 98 patients with advanced-stage cervical cancer and negative PET-CT imaging in the para-aortic areaPatterns of failure after use of (18)F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases.The role of PET/CT in cervical cancer[(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapyFluorodeoxyglucose positron emission tomography-computed tomography in evaluation of pelvic and para-aortic nodal involvement in early stage and operable cervical cancer: Comparison with surgicopathological findings.Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical CancerPrimary tumor SUVmax on preoperative FDG-PET/CT is a prognostic indicator in stage IA2-IIB cervical cancer patients treated with radical hysterectomy.Positron-emission tomography for locally advanced cervical cancer: a survey assessing Canadian practice patterns and access.Preoperative nomogram for the identification of lymph node metastasis in early cervical cancerFDG uptake heterogeneity in FIGO IIb cervical carcinoma does not predict pelvic lymph node involvement.The role of [(18)F]FDG-PET/CT in staging and treatment planning for volumetric modulated Rapidarc radiotherapy in cervical cancer: experience of the European Institute of Oncology, Milan, ItalyFDG-PET-based prognostic nomograms for locally advanced cervical cancer.Functional imaging to predict tumor response in locally advanced cervical cancer.Lymphatic system: a prospective area for advanced targeting of particulate drug carriers.Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.Role of imaging in the pretreatment evaluation of common gynecological cancers.Prognostic Impact of Preoperative Lymph Node Enlargement in Intrahepatic Cholangiocarcinoma: A Multi-Institutional Study by the Kyushu Study Group of Liver Surgery.Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management.PET/CT and MRI in the imaging assessment of cervical cancer.The role of PET-CT in radiotherapy planning of solid tumours.Image-guided radiotherapy and -brachytherapy for cervical cancer.Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial.The Prognostic Value of (18)F-FDG PET/CT for Early Recurrence in Operable Breast Cancer: Comparison with TNM Stage.Association between vascular endothelial growth factor expression and lymph node metastasis in cervical cancer: A meta-analysis.Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.Optimal therapy for IB2 and IIA2 cervical cancer: surgery or chemoradiotherapy?Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.When and how often should PET scans be performed in the management of cervical cancer?Regarding the study testing the addition of gemcitabine to concurrent chemoradiotherapy in cervical carcinoma: Clarity needed.Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?Vascular endothelial growth factor C expression is closely correlated with lymph node recurrence and poor prognosis in patients with early stage cervical cancer.A retrospective comparison of outcome in IB2 and IIA cervical cancer patients treated with primary concurrent chemoradiation versus radical hysterectomy with or without tailored adjuvant therapy.Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.Clinical outcome of extended-field irradiation vs. pelvic irradiation using intensity-modulated radiotherapy for cervical cancer.The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04).
P2860
Q24562146-71AC69D3-D71A-4BD6-B684-BAF60025A2FEQ26750408-001BE121-E848-49C4-8A46-41FF6CD1F652Q26849814-18B00C9B-8A59-4984-9A00-8D0CB78BD1A8Q33407093-D390CDB1-6127-4E42-818C-DC6FE15A3B10Q33709835-A0116D5A-9BFB-4DDD-AC8E-CB90C2C19115Q35584604-D10B712C-9382-4370-B0CD-8D4902A6C14AQ35945537-7A250B05-2011-4E76-B430-0A2BD826B0D9Q36637204-8530AEE7-F1B2-4794-8704-A336B571E37AQ36691460-8BCA96AA-E106-4D18-9D99-CF99CEAD08A0Q36732571-7EF50409-B993-4F2C-9297-653D81379DB0Q36832173-18C022BD-E04A-42A5-9DF3-A0FBB13E0D59Q37204114-D093B989-875F-4292-A9DF-A4A88A607499Q37364585-A45DCA09-E647-4F9F-A383-0ADA87F5CB92Q37459678-E625EAC9-CA3B-45E0-8728-1AD288CFED5EQ37522745-1324E9DC-C55A-49EB-AAC6-E515BBDD780BQ37659146-31DB70E4-B25A-4445-825D-A99149E55D03Q37709704-37EA01FD-A597-4C98-9173-E0537963CE62Q38151507-F1B0EC3A-6017-45B5-8D24-04E5B1DD4A4BQ38172276-A538CDE2-32F9-4022-B790-B88476B45309Q38205397-64DA2E95-9F52-4F13-91DB-521D84FF269AQ38222519-039F9097-F08C-4CD9-8DCF-F9530FEC8797Q38316035-006293D1-80C8-414F-A4A5-D87C1FE25235Q38319587-C3305DCB-786D-4FFA-A7EF-11B804D0D20EQ38350123-A4A488C7-5666-40EF-953C-F78A8D54301BQ38391624-BBB32895-B4BE-4AB0-BA6D-85D7AFC68C69Q38411239-B078F2FB-9187-4FF6-A620-1CF9EC8E3787Q38834289-A53474E2-C63D-44A5-AF3F-494FC428AA19Q39974510-B4C47CFF-BAC3-496B-ACC7-A0C8D98ED7E2Q40686865-BF103FF9-F604-4F04-8F08-6DD20FCCFC3EQ42009404-FDDA782F-68AC-4E38-AFBB-FE9582A1FE03Q42028061-69931AF0-4162-4B7C-9413-801E1B973ECCQ42587608-A2B4F72B-BF1A-4782-86B3-79C858E1F02FQ42964660-E0573C08-2F2B-4B70-94CB-AD029B944327Q43085648-78E4D81E-9A34-4088-A867-B09632934512Q44435039-E0360407-CF8A-4B0B-AD73-4D6B23CFE657Q45212474-8CC58083-1AB3-4498-B472-C49444AD4578Q45722803-94EDD2F8-130D-451A-B504-F3736289EF03Q47409321-5C44E443-8C92-4C8B-91D1-092780EEA4A8Q47654349-1317E9F1-40FD-4019-9F81-A1C2F12384DCQ47695956-336526AE-8867-4F12-AB30-648310BD603E
P2860
Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Lymph node staging by positron ...... er: relationship to prognosis.
@en
Lymph node staging by positron ...... er: relationship to prognosis.
@nl
type
label
Lymph node staging by positron ...... er: relationship to prognosis.
@en
Lymph node staging by positron ...... er: relationship to prognosis.
@nl
prefLabel
Lymph node staging by positron ...... er: relationship to prognosis.
@en
Lymph node staging by positron ...... er: relationship to prognosis.
@nl
P2093
P356
P1476
Lymph node staging by positron ...... er: relationship to prognosis.
@en
P2093
Barry A Siegel
David G Mutch
Elizabeth A Kidd
Farrokh Dehdashti
Janet S Rader
Matthew A Powell
Perry W Grigsby
P304
P356
10.1200/JCO.2009.25.4151
P407
P577
2010-03-22T00:00:00Z